JPMorgan Chase & Co. Cuts Caris Life Sciences (NASDAQ:CAI) Price Target to $30.00

Caris Life Sciences (NASDAQ:CAI) had its target price lowered by JPMorgan Chase & Co. from $35.00 to $30.00 in a research note published on Friday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

A number of other equities research analysts have also recently commented on the stock. The Goldman Sachs Group began coverage on shares of Caris Life Sciences in a research note on Wednesday, April 1st. They issued a “buy” rating and a $27.00 price objective on the stock. Robert W. Baird set a $22.00 price objective on shares of Caris Life Sciences in a research note on Friday. Jefferies Financial Group began coverage on shares of Caris Life Sciences in a research note on Monday, April 13th. They issued a “buy” rating and a $28.00 price objective on the stock. Piper Sandler started coverage on shares of Caris Life Sciences in a research note on Friday, April 10th. They issued a “neutral” rating and a $21.00 price objective on the stock. Finally, Wall Street Zen lowered shares of Caris Life Sciences from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Six investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Caris Life Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $27.56.

Caris Life Sciences Stock Performance

Shares of NASDAQ CAI opened at $16.15 on Friday. The firm has a market cap of $4.56 billion and a PE ratio of -2.12. Caris Life Sciences has a 52 week low of $15.71 and a 52 week high of $42.50. The company has a 50-day simple moving average of $19.15. The company has a debt-to-equity ratio of 0.66, a quick ratio of 7.35 and a current ratio of 7.85.

Caris Life Sciences (NASDAQ:CAI) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.27. The firm had revenue of $292.89 million for the quarter, compared to analysts’ expectations of $281.00 million. Caris Life Sciences had a net margin of 3.75% and a return on equity of 102.71%. The firm’s revenue was up 125.4% on a year-over-year basis. During the same period in the prior year, the company earned ($1.73) EPS. As a group, research analysts expect that Caris Life Sciences will post 0.12 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CAI. Global Retirement Partners LLC lifted its holdings in Caris Life Sciences by 99,900.0% in the 4th quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock valued at $27,000 after purchasing an additional 999 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in Caris Life Sciences by 839.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,644 shares of the company’s stock valued at $29,000 after purchasing an additional 1,469 shares in the last quarter. Olistico Wealth LLC purchased a new position in Caris Life Sciences in the 4th quarter valued at about $31,000. Fifth Third Bancorp purchased a new position in Caris Life Sciences in the 1st quarter valued at about $31,000. Finally, Sterling Capital Management LLC lifted its holdings in shares of Caris Life Sciences by 128.3% during the 1st quarter. Sterling Capital Management LLC now owns 1,927 shares of the company’s stock worth $34,000 after acquiring an additional 1,083 shares during the period.

Key Caris Life Sciences News

Here are the key news stories impacting Caris Life Sciences this week:

• Positive Sentiment: Caris reported strong Q1 2026 results, with total revenue rising 79% year over year to $216.2 million, signaling continued demand for its molecular profiling services. Caris Life Sciences Reports First Quarter 2026 Financial Results
• Positive Sentiment: The company submitted an application to New York State health regulators for authorization to perform Caris Assure blood-based testing on New York specimens, a potentially meaningful commercial expansion for its diagnostic platform. Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood-Based Testing Authorization
• Positive Sentiment: Despite lowering price targets, Citigroup, JPMorgan, and BTIG all kept bullish ratings on CAI, suggesting analysts still see substantial upside from current levels. Benzinga analyst update
• Neutral Sentiment: Investors are still parsing the earnings call transcript and presentation for details on profitability, margin trends, and whether management’s full-year guidance is achievable. Caris (CAI) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Coverage focused on why the stock is down reflects broader concern that valuation remains elevated and that the market may be reacting more to expectations and guidance than to the strong revenue beat. Why Caris Life Sciences, Inc.’s (CAI) Stock Is Down 18.04%
• Negative Sentiment: Multiple analysts cut their price targets after the report, including Citigroup to $28, JPMorgan to $30, and BTIG to $32, which may have weighed on sentiment even though all maintained positive ratings. Analyst price target changes

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.